What additional treatments can be recommended for a patient with hidradenitis suppurativa who is already using twice‑daily topical clindamycin 1% solution and an antiseptic wash?

Additional Treatment Options for Hidradenitis Suppurativa

Add systemic antibiotics with clindamycin 300 mg plus rifampin 300 mg, both twice daily for 8-12 weeks, as this combination achieves response rates of 71-93% and represents the most evidence-based next step for patients already on topical therapy. 1

Immediate Next Steps: Systemic Antibiotic Therapy

Since the patient is already using topical clindamycin and antiseptic washes, escalation to systemic therapy is warranted. The clindamycin-rifampin combination has been studied more extensively than other antibiotic regimens in HS, with systematic reviews demonstrating strong efficacy across 187 patients 1. This regimen can be used as monotherapy in mild-to-moderate disease or as adjuvant therapy in severe cases.

Important Considerations for Antibiotic Selection:

• Duration: Treat for 8-12 weeks initially; can be repeated intermittently as needed
• Monitoring: Watch for gastrointestinal side effects and drug interactions (rifampin induces cytochrome P450 enzymes)
• Resistance mitigation: The concurrent use of antiseptic washes already in place helps reduce antimicrobial resistance risk 1

Additional Topical Optimization

While maintaining current topical clindamycin, consider adding:

• Benzoyl peroxide: Reduces Staphylococcus aureus resistance that develops with topical clindamycin use 1
• Resorcinol 15% cream: Apply twice daily during flares and daily between flares; reduces pain and abscess duration, though irritant dermatitis occurs frequently 1

Intralesional Therapy for Active Lesions

For acute inflammatory nodules, inject intralesional triamcinolone 10 mg/mL (0.2-2.0 mL per lesion), which produces significant pain reduction within 1 day and decreases erythema, edema, suppuration, and lesion size 1. This provides rapid symptomatic relief while systemic therapy takes effect.

Third-Line Options if First-Line Fails

If the clindamycin-rifampin combination proves inadequate after 8-12 weeks:

Triple Antibiotic Therapy:

• Moxifloxacin 400 mg once daily + metronidazole 500 mg three times daily + rifampin 300 mg twice daily
• Complete response rates: 100% in Hurley stage I, 80% in stage II, 17% in stage III 1
• Critical caveat: Stop metronidazole at 6 weeks to avoid neurologic toxicity
• This is typically used as bridge therapy to surgery or long-term immunomodulation

Ertapenem:

• 1 g IV daily for 6 weeks as rescue therapy
• Highly effective but reserved for severe cases due to practical barriers of home infusion and antibiotic resistance concerns 1

Biologic Therapy Consideration

For moderate-to-severe disease unresponsive to antibiotics:

• Adalimumab: FDA-approved for HS in patients aged 12 and older 2
• Infliximab, secukinumab, ustekinumab: Used based on adult data with varying evidence 2

The 2019 North American guidelines 1 emphasize that biologics become necessary when antibiotic regimens fail or in advanced disease where antibiotics serve only an adjunctive role.

Common Pitfalls to Avoid

1. Antibiotic resistance: Topical clindamycin alone increases S. aureus resistance rates 1; the addition of benzoyl peroxide and systemic therapy helps mitigate this
2. Inadequate treatment duration: Systemic antibiotics require full 8-12 week courses; premature discontinuation leads to high recurrence rates
3. Monotherapy in advanced disease: Antibiotics have lower response rates and increased recurrence in severe HS; early consideration of biologics or surgery is essential 1
4. Metronidazole toxicity: When using triple therapy, strictly limit metronidazole to 6 weeks maximum 1

Treatment Algorithm Based on Disease Severity

The evidence supports a stepwise approach:

• Mild disease (Hurley I): Continue current topical therapy + add systemic clindamycin-rifampin
• Moderate disease (Hurley II): Systemic clindamycin-rifampin + intralesional steroids for active lesions + consider benzoyl peroxide
• Severe disease (Hurley III): Systemic antibiotics as adjunct + biologic therapy + surgical consultation

The 2025 guidelines 2 and 2019 North American consensus 1 both emphasize that multimodal treatment stacking—combining topical, systemic, intralesional, and procedural approaches—yields superior outcomes compared to monotherapy at any disease stage.